[1] 陆赛花,吴玮峰,刘秀凤,等.临床药师在呼吸科参与抗菌药物使用的体会[J].中国医院药学杂志,2012,32(8):645-646.
[2] 李雪芹,李云景,卢荣枝,等.临床药师参与317例细菌感染性病例会诊分析[J].中国药物应用与监测,2012,9(3):150-152.
[3] 张波,冯雷,梅丹. 临床药师参与会诊的实践和分析[J].中国医院药学杂志,2014,34(2):148-151.
[4] Quantrill S, Webbe D. Including pharmacists on consultant-led ward rounds[J]. Clin Med, 2011,11(6):627-628.
[5] 丁伯君,邓艳春,文娟.左乙拉西坦添加治疗难治性癫痫的疗效和安全性分析[J].中国临床神经科学,2011,19(2):189-191,198.
[6] 袁展望,李武平,刘冰,等.预防留置导尿管相关感染研究进展[J]. 中国感染控制杂志,2013,12(5):397-399.
[7] 陈晓华,李武平,刘冰,等.泌尿系统感染现状及防治研究进展[J].解放军护理杂志,2015,32(16):38-42,45.
[8] Sarmiento JM, Dockrell DH, Schwab TR,et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients[J]. Clin Transplant, 2000,14(2):136-138.
[9] Kupeli E, Ulubay G, Golak T, et al. Pulmonary complications in renal recipients after transplantation[J]. Transplant Proc,2011,43(2):551-553.
[10] 孙斌,汪泽厚,姚志勇,等. 肾移植术后肺部感染患者免疫抑制剂的调整[J]. 空军总医院学报,2007,23(3):152-156.
[11] Nose K, Oki T, Banno E, et al. Cytomegalovirus infection after prophylactic valganciclovir therapy postkidney transplantation:case reports[J]. Transplant Proc,2012,44(1):296-298.
[12] Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation[J]. Transpl Infect Dis,2011,13(6):551-558.
[13] Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation:current epidemiology and associated risk factors[J]. Clin Transplant, 2006,20(4):401-409.
[14] Dantas SR, Kuboyama RH, Mazzali M, et al. Nosocomial infections in renal transplant patients:risk factors and treatment implications associated with urinary tract and surgical site infections[J]. J Hosp Infect, 2006, 63(2):117-123.
[15] Rubin RH, Wolfson JS, Cosimi AB, et al. Infection in the renal transplant recipient[J]. Am J Med,1981,70(2):405-411.
[16] 郭代红,陈超,李罄,等. 6所医院414例利奈唑胺相关性血小板减少集中监测研究[J].药物流行病学杂志,2013,22(3):109-113.
[17] Chen C, Guo DH, Cao XT, et al. Risk factors for thrombocytopenia in adult Chinese receiving linezolid therapy[J]. Curr Ther Res Clin Exp, 2012,73(6):195-206.
[18] Matsumoto K, Takeda Y, Takeshita A, et al. Renal function as a predictor of linezolid-induced thrombocytopenia[J].Int J Antimicrob Agents,2009,36(2):179-181.
[19] Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction[J]. Int J Antimrcro Agents,2009,33(1):98-99.
[20] Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction[J]. Antimicrob Agents Chemother, 2003,47(9):2775-2780.